178 related articles for article (PubMed ID: 35094010)
21. Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
Gautam N; Kaur M; Kaur S
J Cancer Res Ther; 2021; 17(2):311-326. PubMed ID: 33063698
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of CDCA8 Predicts Poor Prognosis and Promotes Tumor Cell Growth in Prostate Cancer.
Wan S; He Y; Zhang B; Yang Z; Du FM; Zhang CP; Fu YQ; Mi J
Front Oncol; 2022; 12():784183. PubMed ID: 35449575
[TBL] [Abstract][Full Text] [Related]
24. SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways.
Yuan H; Han Y; Wang X; Li N; Liu Q; Yin Y; Wang H; Pan L; Li L; Song K; Qiu T; Pan Q; Chen Q; Zhang G; Zang Y; Tan M; Zhang J; Li Q; Wang X; Jiang J; Qin J
Cancer Cell; 2020 Sep; 38(3):350-365.e7. PubMed ID: 32619406
[TBL] [Abstract][Full Text] [Related]
25. GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers.
Ko HW; Lee HH; Huo L; Xia W; Yang CC; Hsu JL; Li LY; Lai CC; Chan LC; Cheng CC; Labaff AM; Liao HW; Lim SO; Li CW; Wei Y; Nie L; Yamaguchi H; Hung MC
Oncotarget; 2016 Aug; 7(35):57131-57144. PubMed ID: 27494834
[TBL] [Abstract][Full Text] [Related]
26. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
[TBL] [Abstract][Full Text] [Related]
27. Histone trimethylation of the p53 gene by expression of a constitutively active prolactin receptor in prostate cancer cells.
Tan D; Tan S; Zhang J; Tang P; Huang J; Zhou W; Wu S
Chin J Physiol; 2013 Oct; 56(5):282-90. PubMed ID: 24032713
[TBL] [Abstract][Full Text] [Related]
28. SMYD3 regulates gastric cancer progression and macrophage polarization through EZH2 methylation.
Wang P; Zhao L; Rui Y; Ding Y
Cancer Gene Ther; 2023 Apr; 30(4):575-581. PubMed ID: 36127410
[TBL] [Abstract][Full Text] [Related]
29. EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma.
Lian R; Ma H; Wu Z; Zhang G; Jiao L; Miao W; Jin Q; Li R; Chen P; Shi H; Yu W
Mol Cell Biochem; 2018 Feb; 439(1-2):35-43. PubMed ID: 28795320
[TBL] [Abstract][Full Text] [Related]
30. SChLAP1 promotes prostate cancer development through interacting with EZH2 to mediate promoter methylation modification of multiple miRNAs of chromosome 5 with a DNMT3a-feedback loop.
Huang K; Tang Y
Cell Death Dis; 2021 Feb; 12(2):188. PubMed ID: 33589600
[TBL] [Abstract][Full Text] [Related]
31. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
[TBL] [Abstract][Full Text] [Related]
32. MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2.
Pan MZ; Song YL; Gao F
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8795-8805. PubMed ID: 31696466
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
34. Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
Filon M; Gawdzik J; Truong A; Allen G; Huang W; Khemees T; Machhi R; Lewis P; Yang B; Denu J; Jarrard D
Br J Cancer; 2021 Jul; 125(2):247-254. PubMed ID: 33976366
[TBL] [Abstract][Full Text] [Related]
35. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
[TBL] [Abstract][Full Text] [Related]
36. Enhancer of zeste homolog 2 exerts functions in gastric cancer development via modulating microRNA-222-3p methylation and WEE1 expression.
Feng Y; Wang C; Shi T; Liu W; Liu H; Zhu B; Gao F
Chem Biol Drug Des; 2022 Sep; 100(3):320-333. PubMed ID: 35765903
[TBL] [Abstract][Full Text] [Related]
37. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
38. USP44 Promotes the Tumorigenesis of Prostate Cancer Cells through EZH2 Protein Stabilization.
Park JM; Lee JE; Park CM; Kim JH
Mol Cells; 2019 Jan; 42(1):17-27. PubMed ID: 30622230
[TBL] [Abstract][Full Text] [Related]
39. MUC1-C activates EZH2 expression and function in human cancer cells.
Rajabi H; Hiraki M; Tagde A; Alam M; Bouillez A; Christensen CL; Samur M; Wong KK; Kufe D
Sci Rep; 2017 Aug; 7(1):7481. PubMed ID: 28785086
[TBL] [Abstract][Full Text] [Related]
40. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
Nakagawa S; Okabe H; Ouchi M; Tokunaga R; Umezaki N; Higashi T; Kaida T; Arima K; Kitano Y; Kuroki H; Mima K; Nitta H; Imai K; Hashimoto D; Yamashita YI; Chikamoto A; Baba H
HPB (Oxford); 2018 Oct; 20(10):939-948. PubMed ID: 29759640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
